Premium
Evaluation of levamisole as a treatment for amoebic gill disease of Atlantic salmon, Salmo salar L.
Author(s) -
Findlay V L,
Zilberg D,
Munday B L
Publication year - 2000
Publication title -
journal of fish diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 85
eISSN - 1365-2761
pISSN - 0140-7775
DOI - 10.1046/j.1365-2761.2000.00238.x
Subject(s) - levamisole , salmo , biology , immune system , disease , fishery , microbiology and biotechnology , zoology , immunology , fish <actinopterygii> , medicine
Levamisole, a known T‐cell stimulator and immunomodulator in mammals, has been demonstrated to enhance resistance to amoebic gill disease in Atlantic salmon, Salmo salar L. When used in fresh water baths, dose rates of 1.25, 2.5 and 5 ppm levamisole stimulated resistance to reinfection with Paramoeba sp. that was evident from 2–3 weeks post‐treatment. It is proposed that this response is related to enhancement of the non‐specific immune system.